Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits

Summary

A recent study (Fernandez et al., Thromb. Haemostas. 1987; 57: 286-93) demonstrated that when rabbits were injected with the minimum weight of a variety of glycosaminoglycans required to inhibit tissue factor-induced thrombus formation by —80%, exogenous thrombin was inactivated —twice as fast in the post-treatment plasmas as the pre-treatment plasmas. In this study, we investigated the relationship between inhibition of thrombus formation and the extent of thrombin inhibition ex vivo. We also investigated the relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo. Four sulfated polysaccharides (SPS) which influence coagulation in a variety of ways were used in this study. Unfractionated heparin and the fraction of heparin with high affinity to antithrombin III potentiate the antiproteinase activity of antithrombin III. Pentosan polysulfate potentiates the activity of heparin cofactor II. At less than 10 pg/ml of plasma, all three SPS also inhibit intrinsic prothrombin activation. The fourth agent, dermatan sulfate, potentiates the activity of heparin cofactor II but fails to inhibit intrinsic prothrombin activation even at concentrations which exceed 60 pg/ml of plasma. Inhibition of thrombus formation by each sulfated polysaccharides was linearly related to the extent of thrombin inhibition achieved ex vivo. These observations confirm the utility of catalysis of thrombin inhibition as an index for assessing antithrombotic potential of glycosaminoglycans and other sulfated polysaccharides in rabbits. With the exception of pentosan polysulfate, there was no clear relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo.

Keywords

Antithrombotic effects - Thrombin inhibition - Sulfated poly-saccharides

• References

• 1 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin inhibition to the antithrombotic effect of heparin. Blood 1985; 65: 198-201
• 2 Holmer E, Mattson C, Nilsson S. Anticoagulant and antithrombotic effects of low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 3 Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DR. Low-affinity heparin potentiates the action of high affinity oligosaccharides. Thromb Res 1984; 34: 125-134
• 4 Boneu B, Buchanan MR, Cade JF, Van Ryan J, Fernandez FA, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans in thrombus growth in vivo. Thromb Res 1985; 40: 81-89
• 5 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity to antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-249
• 6 Fernandez F, Van Ryan J, Ofosu FA, Hirsh J, Buchanan MR. Thé hemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986; 64: 309-317
• 7 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulfate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
• 8 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds) Leuven University Press; Leuven: 1987: 17-36
• 9 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic pentasaccharide in a rabbit stasis model using different thrombogenic challenges. Thromb Res 1987; 467: 187-198
• 10 Fernandez FA, Buchanan MR, Hirsh J, Fenton JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemostas 1987; 57: 286-293
• 11 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1986; 485: 41-55
• 12 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Hirsh J. The inhibition of thrombin-dependent feedback reactions is critical to the expression of the anticoagulant effects of heparin. Biochem J 1987; 243: 579-588
• 13 Ofosu FA, Buchanan MR, Anvari N, Smith LM, Blajchman MA. Plasma anticoagulant mechanisms of heparin, heparan sulfate and dermatan sulfate. Ann NY Acad Sci 1988 (in press).
• 14 Modi GJ, Blajchman MA, Ofosu FA. The isolation of prothrombin, factor IX and factor X from Factor IX Concentrates. Thromb Res 1984; 36: 537-547
• 15 Ofosu FA, Smith LM, Anvari N, Blajchman MA. An approach to assigning in vitro potency to low molecular weight heparins based on the catalysis of thrombin inhibition and the inhibition of prothrombin activation. Thromb Haemostas 1988; 60: 193-198
• 16 Sie P, Ofosu FA, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective roles of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and various sulfated polysaccharides. Br J Haematol 1986; 64: 707-714
• 17 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2164-2169
• 18 Barrowcliffe TW, Gray E, Merton RE, Dawes J, Jennings CA, Hubbard AR, Thomas DP. Anticoagulant activities of pentosan polysulfate (Hemoclar) due to the release of hepatic triglyceride lipase (HTGL). Thromb Haemostas 1986; 56: 202-206
• 19 Gray E, Bengtsson-Olivecrona G, Olivecrona T, Barrowcliffe TW. Anti-Xa activity of human hepatic triglyceride lipase. J Lab Clin Med 1987; 109: 653-659
• 20 Olson TA, Sonder SA, Wilner GD, Fenton II JW. Heparin binding in proximity to the catalytic site of human thrombin. Ann NY Acad Sci 1986; 485: 96-103
• 21 Berliner LJ, Sugawara Y, Fenton II JW. Human α-thrombin binding to non-polymerized fibrin-Sepharose: evidence for anionic binding region. Biochemistry 1985; 24: 7005-7009